Smith RJH, Appel GB, Blom AM et al (2019) C3 glomerulopathy-understanding a rare complement-driven renal disease. Nat Rev Nephrol 15:129–143. https://doi.org/10.1038/s41581-018-0107-2

Article  PubMed  PubMed Central  Google Scholar 

Meuleman MS, Roquigny J, Brousse R et al (2025) Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN. Nephrol Dial Transplant 40:842–851. https://doi.org/10.1093/ndt/gfae245

Article  CAS  PubMed  Google Scholar 

Rovin BH, Caster DJ, Cattran DC et al (2021) Executive summary of the KDIGO guideline for the management of glomerular diseases. Kidney Int 100:753–779. https://doi.org/10.1016/j.kint.2021.05.015

Article  PubMed  Google Scholar 

Sethi S, Fervenza FC, Zhang Y, Zand L et al (2013) Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83:293–299. https://doi.org/10.1038/ki.2012.384

Article  CAS  PubMed  Google Scholar 

Heiderscheit AK, Hauer JJ, Smith RJH (2022) C3 glomerulopathy: understanding an ultra-rare complement-mediated renal disease. Am J Med Genet C Semin Med Genet 190:344–357. https://doi.org/10.1002/ajmg.c.31986

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizerska-Wasiak M (2023) How to take advantage of easily available biomarkers in patients with IgA nephropathy: IgA and C3 in serum and kidney biopsy. Pediatr Nephrol 38:1439–1448. https://doi.org/10.1007/s00467-022-05644-9

Article  PubMed  Google Scholar 

Kavanagh D, Ariceta G, Vivarelli M, Schaefer F, Caravaca-Fontán F et al (2025) Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis. Kidney Int Rep 11:17–31. https://doi.org/10.1016/j.ekir.2025.10.020

Article  PubMed  PubMed Central  Google Scholar 

Cappoli A, Kersnik-Levart T, Silecchia V, Ariceta G et al (2025) C3 glomerulopathy in children: a longitudinal study evaluating outcome. Pediatr Nephrol 40:979–986. https://doi.org/10.1007/s00467-024-06587-z

Article  PubMed  Google Scholar 

Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL et al (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72:84–92. https://doi.org/10.1053/j.ajkd.2017.11.019

Article  CAS  PubMed  Google Scholar 

Welte T, Arnold F, Westermann L, Rottmann FA et al (2023) Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrol 24:8. https://doi.org/10.1186/s12882-023-03058-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duineveld C, van de Kar NCAJ, Wetzels JFM (2018) Benefit of eculizumab compared to standard of care still unproven in C3 glomerulopathy. Am J Kidney Dis 72:906. https://doi.org/10.1053/j.ajkd.2018.07.013

Article  PubMed  Google Scholar 

Nester C, Smith R, Kavanagh D, Vivarelli M et al (2025) Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study. Kidney Int Rep 10(Suppl 2):S136–S137. https://doi.org/10.1016/j.ekir.2024.11.300

Article  Google Scholar 

Nester CM, Bomback AS, Ariceta MG, Delmas Y et al (2024) VALIANT: a randomized, multicenter, double-blind, placebo-controlled Phase 3 trial of pegcetacoplan for patients with C3G or primary IC-MPGN. J Am Soc Nephrol 35(10 Suppl):SA-OR92. https://doi.org/10.1681/ASN.2024qdwvz5bg

Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, de Neves Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM, VALIANT Trial Investigators Group (2025) Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. N Engl J Med 393:2210–2220. https://doi.org/10.1056/NEJMoa2501510

Article  CAS  PubMed  Google Scholar 

Mancuso M, Cugno M, Griffini S, Grovetti E et al (2025) Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy. Pediatr Nephrol 40:1959–1963. https://doi.org/10.1007/s00467-025-06673-w

Article  PubMed  Google Scholar